Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654008 | 1.00 | MAOB (0.41) | MAOBRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28857568 | 0.84 | MAOB (0.39) | MAOBRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29772131 | 0.84 | MAOB (0.39) | MAOBRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31524043 | 0.82 | MAOB (0.38) | MAOBRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2264653 | 0.82 | SMN1; SMN2 (0.43) | RAB9AMAPTSMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL12365194 | 0.81 | SMN1; SMN2 (0.42) | RAB9AMAPTSMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL12365664 | 0.79 | RAB9A (0.41) | RAB9AMAPTSMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL19085282 | 0.78 | MAOB (0.38) | MAOBMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL8462129 | 0.75 | MAOB (0.46) | MAOBRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL24735866 | 0.74 | MTNR1A (0.51) | RAB9AMAPTSMN1; SMN2ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350270-B2 | Antimalarial agents | MSD R&D (CHINA) CO. LTD. (CN) | 2025-07-08 | — | — | US | disclosed |
| CN-114555564-B | Antimalarial drugs | 默沙东公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4216957-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | Merck Sharp & Dohme LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-4013742-A1 | ANTIMALARIAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555564-A | Antimalarial drugs | 默沙东公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022066545-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021027502-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350270-B2 | Antimalarial agents | CTSL, SERPINA3, SERPINB1 | MAOB 2711/4885RAB9A 1433/4885MAPT 2167/4885 |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | CTSL, PRCP, CPB1 | MAOB 4140/4885RAB9A 733/4885MAPT 2665/4885 |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | CTSL, SERPINA3, SERPINB1 | MAOB 2711/4885RAB9A 1433/4885MAPT 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.